MedTrace Logo

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

NCT01879020 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2013-06-17

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TA-8995 after multiple doses in healthy adult male subjects

Conditions

Interventions

DRUG

TA-8995

Drug: TA-8995 1mg

DRUG

TA-8995

Drug: TA-8995 2.5mg

DRUG

TA-8995

Drug: TA-8995 5mg

DRUG

TA-8995

Drug: TA-8995 10mg

DRUG

TA-8995

Drug: TA-8995 25mg

DRUG

Placebo

Placebo (TA-8995 1mg)

DRUG

Placebo

Placebo (TA-8995 2.5mg)

DRUG

Placebo

Placebo (TA-8995 5mg)

DRUG

Placebo

Placebo (TA-8995 10mg)

DRUG

Placebo

Placebo (TA-8995 25mg)

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Werner Weber, MD · Momentum Pharma Services GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01879020 on ClinicalTrials.gov